1 hr ago

Karnataka Seeks Wider Price Caps for Life-Saving Medicines

Karnataka Seeks Wider Price Caps for Life-Saving Medicines
Karnataka urges Centre to extend cancer drug price caps to other life-saving medicines · theprint.in

Karnataka wants the national government to limit how much extra can be added to the prices of some important medicines.

A proposed rule would limit trade margins on certain cancer medicines to 30% of their maximum retail price.

Officials still need to decide which medicines will be included.

Karnataka also wants similar rules for costly medicines used for heart and kidney conditions.

The state says its checks found concerns about prices for 253 medicines and medical supplies.

Hospitals and other healthcare institutions have been advised to show medicine costs and retail prices on bills starting November 1.

The Centre estimates the cancer-drug measure could lower some prices by 20% to 70%.

It says patients could save around Rs 2,500 crore.

Key facts

Proposed cancer-drug trade-margin cap
30% of MRP for identified non-scheduled anti-cancer medicines, subject to finalising the medicine list.
NPPA approval
In-principle approval was granted at a meeting on October 8.
Expert committee deadline
A committee under the Directorate General of Health Services is expected to recommend covered medicines by October 14.
Medicines and supplies reviewed
Karnataka cited pricing concerns identified in 253 medicines and medical consumables.
Hospital billing advisory
Healthcare institutions were advised to list purchase cost and MRP on bills from November 1.
Centre's estimated price reduction
MRPs of several cancer medicines could fall by 20% to 70%.
Estimated patient savings
The Centre estimates the measure could save patients around Rs 2,500 crore.

Quotes

Karnataka state government

The state government, making a request in a press release.

“The state government also hereby requests the Union Government to extend this capping to other essential life-saving medicines necessary for treatment of cardiac, kidney ailments etc. particularly high cost drugs, to reduce the burden of treatment in terms of cost to the common man.”
theprint.in

Sources

Related news